Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance

OBJECTIVE—Defects in glucagon-like peptide 1 (GLP-1) secretion have been reported in some patients with type 2 diabetes after meal ingestion. We addressed the following questions: 1) Is the quantitative impairment in GLP-1 levels different after mixed meal or isolated glucose ingestion? 2) Which endogenous factors are associated with the concentrations of GLP-1? In particular, do elevated fasting glucose or glucagon levels diminish GLP-1 responses? RESEARCH DESIGN AND METHODS—Seventeen patients with mild type 2 diabetes, 17 subjects with impaired glucose tolerance, and 14 matched control subjects participated in an oral glucose tolerance test (75 g) and a mixed meal challenge (820 kcal), both carried out over 240 min on separate occasions. Plasma levels of glucose, insulin, C-peptide, glucagon, triglycerides, free fatty acids (FFAs), gastric inhibitory polypeptide (GIP), and GLP-1 were determined. RESULTS—GIP and GLP-1 levels increased significantly in both experiments (P < 0.0001). In patients with type 2 diabetes, the initial GIP response was exaggerated compared with control subjects after mixed meal (P < 0.001) but not after oral glucose ingestion (P = 0.98). GLP-1 levels were similar in all three groups in both experiments. GIP responses were 186 ± 17% higher after mixed meal ingestion than after the oral glucose load (P < 0.0001), whereas GLP-1 levels were similar in both experiments. There was a strong negative association between fasting glucagon and integrated FFA levels and subsequent GLP-1 concentrations. In contrast, fasting FFA and integrated glucagon levels after glucose or meal ingestion and female sex were positively related to GLP-1 concentrations. Incretin levels were unrelated to measures of glucose control or insulin secretion. CONCLUSIONS—Deteriorations in glucose homeostasis can develop in the absence of any impairment in GIP or GLP-1 levels. This suggests that the defects in GLP-1 concentrations previously described in patients with long-standing type 2 diabetes are likely secondary to other hormonal and metabolic alterations, such as hyperglucagonemia. GIP and GLP-1 concentrations appear to be regulated by different factors and are independent of each other.

[1]  J. Holst,et al.  The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas , 2007, Diabetologia.

[2]  Sten Madsbad,et al.  Reduced Incretin Effect in Type 2 Diabetes , 2007, Diabetes.

[3]  J. Holst,et al.  Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects , 2007, Diabetologia.

[4]  J. Holst,et al.  Reduced Incretin Effect in Type 2 Diabetes - Cause or Consequence of the Diabetic State? Received for publication 23 January 2007 and accepted in revised form 3 May 2007. , 2007 .

[5]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[6]  Sten Madsbad,et al.  Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. , 2006, European journal of endocrinology.

[7]  Reawika Chaikomin,et al.  Effects of fat on gastric emptying of and the glycemic, insulin, and incretin responses to a carbohydrate meal in type 2 diabetes. , 2006, The Journal of clinical endocrinology and metabolism.

[8]  J. Holst,et al.  Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. , 2006, Gastroenterology.

[9]  M. Nauck,et al.  Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes , 2006, Diabetologia.

[10]  J. Holst,et al.  Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans , 2006, Diabetologia.

[11]  J. Holst,et al.  Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes , 2005, Diabetologia.

[12]  M. Nauck,et al.  Glucagon‐like peptide 1(GLP‐1) in biology and pathology , 2005, Diabetes/metabolism research and reviews.

[13]  W. Creutzfeldt,et al.  The incretin concept today , 1979, Diabetologia.

[14]  M. Nauck,et al.  Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. , 2004, Diabetes.

[15]  M. Nauck,et al.  Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide , 2004 .

[16]  Jens J. Holst,et al.  Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes , 2004, Regulatory Peptides.

[17]  J. Holst,et al.  Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. , 2004, American journal of physiology. Endocrinology and metabolism.

[18]  J. Alvarado,et al.  Endothelia of Schlemm's canal and trabecular meshwork: distinct molecular, functional, and anatomic features. , 2004, American journal of physiology. Cell physiology.

[19]  J. Wishart,et al.  Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects , 1993, Diabetologia.

[20]  J. Holst,et al.  Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients , 1993, Diabetologia.

[21]  J. Wishart,et al.  Gastric and oesophageal emptying in patients with Type 2 (non-insulin-dependent) diabetes mellitus , 1989, Diabetologia.

[22]  W. Creutzfeldt,et al.  New developments in the incretin concept , 1985, Diabetologia.

[23]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[24]  T. M. Hayes,et al.  The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with Type 2 (non-insulin-dependent) diabetes mellitus , 2004, Diabetologia.

[25]  J. Holst,et al.  Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. , 2003, The Journal of clinical endocrinology and metabolism.

[26]  J. Holst,et al.  Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia , 2003, Diabetologia.

[27]  J. Holst,et al.  The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. , 2003, Diabetes.

[28]  L. Geddes.  The first accurate measurement of systolic and diastolic blood pressure , 2002, IEEE Engineering in Medicine and Biology Magazine.

[29]  M. Nauck,et al.  Gastric Inhibitory Polypeptide: the neglected incretin revisited , 2002, Regulatory Peptides.

[30]  M. Horowitz,et al.  Gastric emptying in diabetes: clinical significance and treatment , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[31]  J. Holst,et al.  Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. , 2001, Diabetes.

[32]  J. Holst,et al.  Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. , 2001, The Journal of clinical endocrinology and metabolism.

[33]  J. Holst,et al.  Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. , 2001, Diabetes.

[34]  J. Holst,et al.  Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. , 2000, The Journal of clinical endocrinology and metabolism.

[35]  J. Holst,et al.  In vivo and in vitro degradation of glucagon-like peptide-2 in humans. , 2000, The Journal of clinical endocrinology and metabolism.

[36]  J. Holst,et al.  Structure, measurement, and secretion of human glucagon-like peptide-2 , 2000, Peptides.

[37]  Rolf Mentlein,et al.  Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides , 1999, Regulatory Peptides.

[38]  J. Holst,et al.  Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations , 1999, Diabetologia.

[39]  J. Holst,et al.  The pathogenesis of NIDDM involves a defective expression of the GIP receptor , 1997, Diabetologia.

[40]  T. Usdin,et al.  Chronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic rats. , 1996, The American journal of physiology.

[41]  M. Nauck,et al.  Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. , 1993, The Journal of clinical endocrinology and metabolism.

[42]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.

[43]  J. Holst,et al.  Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. , 1991, The Journal of clinical investigation.

[44]  T. Jenssen,et al.  Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. , 1990, Diabetes.

[45]  J. Holst,et al.  Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. , 1988, Endocrinology.

[46]  T. Krarup.  Immunoreactive gastric inhibitory polypeptide. , 1988, Endocrine reviews.

[47]  R. Rizza,et al.  Incretin Effect Due to Increased Secretion and Decreased Clearance of Insulin in Normal Humans , 1988, Diabetes.

[48]  S. Madsbad,et al.  Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus. , 1987, Metabolism: clinical and experimental.

[49]  J. Holst,et al.  Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. , 1986, Endocrinology.

[50]  R. Eaton,et al.  Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. , 1986, The Journal of clinical endocrinology and metabolism.

[51]  J. Holst.  Evidence that peak II GLI or enteroglucagon is identical to the C-terminal sequence (residues 33–69) of glicentin , 1983, Regulatory Peptides.

[52]  J. Holst.  Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin. , 1982, The Biochemical journal.

[53]  J. Halter,et al.  Insulin secretion in diabetes mellitus. , 1981, The American journal of medicine.

[54]  J. Brown,et al.  Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas. , 1978, Endocrinology.

[55]  J. Brown,et al.  Hypersecretion of Gastric Inhibitory Polypeptide Following Oral Glucose in Diabetes Mellitus , 1977, Diabetes.

[56]  W. A. Müller,et al.  Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. , 1970, The New England journal of medicine.